United States
Print page content Print
Increase text size Decrease text size
Text Size
CYTOPOINT is now approved for the treatment of allergic dermatitis! Learn more
Cytopoint logo

This site is intended for U.S.
animal healthcare professionals

CYTOPOINT® treatment efficacy

CYTOPOINT® treatment efficacy

CYTOPOINT helps relieve itch in dogs within 24 hours while giving skin time to heal after only one injection1

Effective itch relief within one day

  • A single injection of CYTOPOINT was shown to significantly decrease IL-31-induced pruritus in dogs within one day of injection and for 28 days2
  • CYTOPOINT decreased pruritus by >50% in all dogs at Day 1 and in 95% of dogs at Day 282
CYTOPOINT Canine Itch Relief Efficacy Chart
  • Least squares mean (±SE).
  • Day-7 means are arithmetic mean values.
  • Statistically significant (P<0.0001) compared to placebo.

Fast, lasting canine itch relief

  • CYTOPOINT starts working in 24 hours, continues working for 4 to 8 weeks* after 1 injection to help reduce pruritus and lesions associated with canine atopic dermatitis1

CYTOPOINT Canine Itch Relief Efficacy Chart
CYTOPOINT VAS Efficacy Score Chart

Defining treatment success

  • Repeat administration every 4 to 8 weeks as needed in individual patients.1
  • Successful canine pruritus relief was defined as a reduction in pruritus score of ≥20 mm on the visual analog scale (VAS). VAS is an owner-assessed scale that measures itch along a continuum from normal dog (no itch) to extremely severe itch, using numbers from 0 to 100. VAS scoring instruments were given to owners, accompanied by explanations of how to record itch based on the behavior of the dog. Owners recorded itch on Days 1, 2, 3, 7 and every 7 days thereafter.1
  • Statistically significant compared to placebo (P≤0.05).
  • §Day 0 means are arithmetic mean values.

CYTOPOINT gives damaged skin a chance to heal after 1 injection1

CYTOPOINT canine skin improvement
CADESI-03 scores after CYTOPOINT

Defining treatment success

  • Treatment success was defined as a ≥50% reduction from baseline in skin condition scores as assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and self-induced alopecia at 62 body sites.1
  • Statistically significant compared to placebo (P≤0.05).
  • Day 0 means are arithmetic mean values.
CADESI-O3 measures CYTOPOINT efficacy

See Coco’s CYTOPOINT story

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.